Latest revenue
$150.8M
as of 2026-03-31
Latest net income
$-13.5M
as of 2026-03-31
Net margin
-8.9%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.02B
- Enterprise value
- $3.02B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $26.45
- 52-wk low
- $8.31
- Beta
- —
- Shares out
- 127.7M
5-year trend
What this company does
Item 1. Business. Overview Our mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled the deployment of our rapidly expanding suite of products, which allow our customers to interrogate biological…
AI summary unavailable — showing raw filing excerpt
Generated from TXG's filing dated 2026-02-13
Key risks
Item 1A. Risk Factors. Investing in our Class A common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report including our financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our Class A common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, cash flows and prospects. In such an event, the market price of our Class A common stock could decline and you may lose all…
AI summary unavailable — showing raw filing excerpt
Generated from TXG's filing dated 2026-02-13
Profitability
Gross margin
69.1%
1.8%Operating margin
-9.5%
70.2%Net margin
-6.8%
77.3%Return on equity
-5.5%
78.7%Return on assets
-4.2%
79.0%Leverage
Debt / equity
0.31×
4.8%Debt / assets
23.5%
3.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $150.8M | -2.6% | $-13.5M | +60.8% | -8.9% |
Q4 2025 2025-12-31 | $166.0M | +0.6% | $17.9M | +136.6% | 10.8% |
Q3 2025 2025-09-30 | $149.0M | -1.7% | $-27.3M | +23.7% | -18.3% |
Q2 2025 2025-06-30 | $172.9M | +12.9% | $180.0K | +100.5% | 0.1% |
Q1 2025 2025-03-31 | $154.9M | +9.8% | $-34.4M | +42.7% | -22.2% |
Q4 2024 2024-12-31 | $165.0M | — | $-49.0M | — | -29.7% |
Q3 2024 2024-09-30 | $151.7M | -1.3% | $-35.8M | +61.6% | -23.6% |
Q2 2024 2024-06-30 | $153.1M | +4.3% | $-37.9M | +39.3% | -24.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Laboratory Analytical Instruments · SIC 3826
Your notes
Keep private notes on TXG — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$2.6M
Net activity
−$2.6M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns TXG
Institutional value
$1.30B
Total shares held
61.3M
Distinct holders
194
-125 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 11.7M | $248.8M | -950.1K (-7.5%) | Trimmed |
| 2 | BlackRock, Inc. | 10.1M | $214.0M | +65.5K (+0.7%) | Added |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.9M | $146.8M | — | New |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 5.3M | $111.9M | — | New |
| 5 | Sumitomo Mitsui Trust Group, Inc. | 5.1M | $108.5M | -382.0K (-7.0%) | Trimmed |
| 6 | Nikko Asset Management Americas, Inc. | 5.1M | $108.3M | -382.0K (-7.0%) | Trimmed |
| 7 | DIMENSIONAL FUND ADVISORS LP | 2.0M | $43.4M | +525.4K (+34.6%) | Added |
| 8 | Capital World Investors | 1.5M | $30.8M | +0 (+0.0%) | No change |
| 9 | Connor, Clark & Lunn Investment Management Ltd. | 938.4K | $19.9M | +228.8K (+32.2%) | Added |
| 10 | VANGUARD FIDUCIARY TRUST CO | 778.9K | $16.5M | — | New |
| 11 | JPMORGAN CHASE & CO | 785.5K | $15.6M | -142.9K (-15.4%) | Trimmed |
| 12 | Nuveen, LLC | 625.8K | $13.3M | +389.4K (+164.7%) | Added |
| 13 | FEDERATED HERMES, INC. | 611.6K | $13.0M | -33.3K (-5.2%) | Trimmed |
| 14 | IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 542.8K | $11.5M | -89.3K (-14.1%) | Trimmed |
| 15 | UBS Group AG | 494.8K | $10.5M | -366.2K (-42.5%) | Trimmed |
| 16 | Sands Capital Ventures, LLC | 481.8K | $10.2M | +0 (+0.0%) | No change |
| 17 | Russell Investments Group, Ltd. | 480.6K | $10.2M | -53.3K (-10.0%) | Trimmed |
| 18 | Quantedge Capital Pte Ltd | 416.6K | $8.8M | +212.6K (+104.2%) | Added |
| 19 | Simplify Asset Management Inc. | 354.7K | $7.5M | -131.3K (-27.0%) | Trimmed |
| 20 | Bank of New York Mellon Corp | 347.6K | $7.4M | -3.4K (-1.0%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once TXG's latest filing finishes processing.